Related Experiment Video
Updated: Nov 19, 2025

Author Spotlight: Evaluating Traditional Chinese Therapy for Ankylosing Spondylitis in Mice
Published on: October 27, 2023
Differences in biologics for treating ankylosing spondylitis: the contribution of network meta-analysis
A Migliore1, G Gigliucci, D Integlia
1Operative Unit of Rheumatology, San Pietro Fatebenefratelli Hospital, Rome, Italy. migliore.alberto60@gmail.com.
Objective:
Ankylosing Spondylitis (AS) is a chronic form of arthritis of unknown origin affecting the spine. In this study, we aimed to identify clinical and safety profiles of adalimumab, certolizumab pegol, etanercept, golimumab, infliximab, and secukinumab that are biologic agents (biologics) mainly used for the treatment of AS, and to understand differences between them.
Materials And Methods:
An extensive literature research was performed in MEDLINE and EMBASE in order to identify all network meta-analysis (NMA) and/or mixed treatment comparison (MTC) papers. NMA and/or MTC, with a ranking of the effectiveness of biologics in AS, were included in the analysis, and the adhesion to ISPOR guidelines was investigated.
Results:
60 studies were identified; after applying exclusion criteria methods, 7 studies underwent further analysis. Infliximab was the drug that exhibited the highest probability for achieving clinical efficacy by ASAS20 at 12 and 24 weeks. Considering only subcutaneous biologics, Golimumab achieved the highest probability for achieving the ASAS20 response at 12 weeks.
Conclusions:
Results from NMA on the use of biologics in AS indicates infliximab emerged as the drug with the highest probability of obtaining ASAS20 response both at 12 and 24 weeks of treatment.
More Related Videos
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drug Products: Biologics, Biosimilars and Interchangeables
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Bioequivalence of Drugs: Drugs with Multiple Indications
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Bioequivalence studies: Biowaivers

